Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity
Roche will share in developing and commercializing petrelintide, a clinical-stage Zealand Pharma drug that activates the amylin receptor to spark weight loss. This agreement represents the highest total financial consideration in the obesity field to date.